Observational Study Finds Medical Cannabis Products Improve Health-Related Quality of Life in Patients with Chronic Illnesses
LOS ANGELES– A new study has found that medical cannabis products are generally well-tolerated and can lead to significant improvements in the health-related quality of life of patients. The research, published in the journal Expert Review of Clinical Pharmacology, assessed the safety and efficacy of cannabis-derived products in 2,833 patients enrolled in the UK Medical Cannabis Registry. All participants had been authorized by their doctors to use cannabis-based medicinal products, which have been available since 2018 to patients unresponsive to conventional medications.
The patients enrolled in the study suffered from a range of conditions, including chronic pain, anxiety, post-traumatic stress, depression, migraine, inflammatory bowel disease, and other afflictions. The participants consumed cannabis by either vaporizing marijuana flowers or by ingesting plant-derived extracts containing both THC and CBD. Researchers assessed their symptoms compared to baseline at one, three, six, and twelve months.
The study found that most patients experienced sustained improvements following cannabis therapy, and that adverse events associated with cannabis were typically mild, with dry mouth and fatigue being the most frequently reported side-effects. However, the authors noted that female and cannabis-naïve patients were at increased risk of experiencing adverse events, and that the risk of such events should be considered before initiating treatment.
The authors concluded that the findings could help inform current clinical practice, but also highlighted the need for further clinical trials to determine causality and generate guidelines to optimize therapy with cannabis-based medicinal products. Overall, the study suggests that medical cannabis products can have a positive impact on the quality of life of patients with chronic illness, but more research is needed to fully understand their benefits and risks.
Here the full text of study “An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry”
Latest News
Schwazze Posts $18.5 Million Loss in 2022 Due to Expansion into New Mexico and Acquisitions, But Sees Strong Revenue Growth and Retail Sales
LOS ANGELES-- Schwazze Inc., formerly known as Medicine Man Technologies Inc. and based in Denver, Colorado, has reported a net loss of $18.5 million for the full year of 2022, a significant downturn from its ...
Columbia Care reports $300 million net loss for Q4 2022 and strategic restructuring efforts
LOS ANGELES-- Columbia Care Inc. recently reported its financial results for the fourth quarter and full year ended Dec. 31, 2022, revealing a net loss of $300 million for the quarter, compared to a net ...
Aurora Cannabis Saves $2.6 Million in Interest Payments Through Repurchase of Convertible Senior Notes
LOS ANGELES-- Canadian cannabis company Aurora Cannabis Inc. has announced that it has repurchased approximately $46.6 million (US$34.3 million) worth of its convertible senior notes. The Notes were repurchased at a total cost, including accrued ...